Narrowband ultraviolet b phototherapy in childhood vitiligo: Evaluation of results in 28 patients

Serena Percivalle, Roberta Piccinno, Massimo Caccialanza, Stella Forti

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Phototherapy using narrowband ultraviolet B (UVB) is considered among the treatments of choice in vitiligo, even in childhood. The objective of the current study was to evaluate the profile of safety and effectiveness of such therapy in a group of children. An open, uncontrolled study was performed on 28 children with vitiligo who were receiving narrow band UVB phototherapy. The children were classified according to vitiligo type and phototype. Family history and presence of thyroid disease were investigated. Eighteen patients had received other treatments that was stopped 3 months before starting phototherapy. Phototherapy was administered twice a week. The mean duration of therapy was 10 ± 3.4 months. The mean total dose administered was 156.12 ± 79.4 J/cm 2. Photographs of lesions were taken before and at the end of treatment. The response to phototherapy was expressed as percentage of repigmentation. The data were statistically analyzed using SPSS (SPSS Inc., Chicago, IL). Fourteen percent of patients showed excellent response, 28.6% good response, 25% moderate response, and 28.6% mild response; the remaining 3.5% were not responsive. No side effects were observed except mild erythema requiring a decrease in dosage in a few patients. The results of the present study confirm those of other authors, with better results than adults probably related to good adherence of patients and their families. Nevertheless, high cumulative doses are not necessarily related to a good response. Therefore, we suggest stopping treatment after 6 months in nonresponding cases.

Original languageEnglish
Pages (from-to)160-165
Number of pages6
JournalPediatric Dermatology
Volume29
Issue number2
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Vitiligo
Phototherapy
Therapeutics
Thyroid Diseases
Erythema
Patient Compliance
Safety

ASJC Scopus subject areas

  • Dermatology
  • Pediatrics, Perinatology, and Child Health

Cite this

Narrowband ultraviolet b phototherapy in childhood vitiligo : Evaluation of results in 28 patients. / Percivalle, Serena; Piccinno, Roberta; Caccialanza, Massimo; Forti, Stella.

In: Pediatric Dermatology, Vol. 29, No. 2, 03.2012, p. 160-165.

Research output: Contribution to journalArticle

@article{86d146f99b2246df92f014f598f4799a,
title = "Narrowband ultraviolet b phototherapy in childhood vitiligo: Evaluation of results in 28 patients",
abstract = "Phototherapy using narrowband ultraviolet B (UVB) is considered among the treatments of choice in vitiligo, even in childhood. The objective of the current study was to evaluate the profile of safety and effectiveness of such therapy in a group of children. An open, uncontrolled study was performed on 28 children with vitiligo who were receiving narrow band UVB phototherapy. The children were classified according to vitiligo type and phototype. Family history and presence of thyroid disease were investigated. Eighteen patients had received other treatments that was stopped 3 months before starting phototherapy. Phototherapy was administered twice a week. The mean duration of therapy was 10 ± 3.4 months. The mean total dose administered was 156.12 ± 79.4 J/cm 2. Photographs of lesions were taken before and at the end of treatment. The response to phototherapy was expressed as percentage of repigmentation. The data were statistically analyzed using SPSS (SPSS Inc., Chicago, IL). Fourteen percent of patients showed excellent response, 28.6{\%} good response, 25{\%} moderate response, and 28.6{\%} mild response; the remaining 3.5{\%} were not responsive. No side effects were observed except mild erythema requiring a decrease in dosage in a few patients. The results of the present study confirm those of other authors, with better results than adults probably related to good adherence of patients and their families. Nevertheless, high cumulative doses are not necessarily related to a good response. Therefore, we suggest stopping treatment after 6 months in nonresponding cases.",
author = "Serena Percivalle and Roberta Piccinno and Massimo Caccialanza and Stella Forti",
year = "2012",
month = "3",
doi = "10.1111/j.1525-1470.2011.01683.x",
language = "English",
volume = "29",
pages = "160--165",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Narrowband ultraviolet b phototherapy in childhood vitiligo

T2 - Evaluation of results in 28 patients

AU - Percivalle, Serena

AU - Piccinno, Roberta

AU - Caccialanza, Massimo

AU - Forti, Stella

PY - 2012/3

Y1 - 2012/3

N2 - Phototherapy using narrowband ultraviolet B (UVB) is considered among the treatments of choice in vitiligo, even in childhood. The objective of the current study was to evaluate the profile of safety and effectiveness of such therapy in a group of children. An open, uncontrolled study was performed on 28 children with vitiligo who were receiving narrow band UVB phototherapy. The children were classified according to vitiligo type and phototype. Family history and presence of thyroid disease were investigated. Eighteen patients had received other treatments that was stopped 3 months before starting phototherapy. Phototherapy was administered twice a week. The mean duration of therapy was 10 ± 3.4 months. The mean total dose administered was 156.12 ± 79.4 J/cm 2. Photographs of lesions were taken before and at the end of treatment. The response to phototherapy was expressed as percentage of repigmentation. The data were statistically analyzed using SPSS (SPSS Inc., Chicago, IL). Fourteen percent of patients showed excellent response, 28.6% good response, 25% moderate response, and 28.6% mild response; the remaining 3.5% were not responsive. No side effects were observed except mild erythema requiring a decrease in dosage in a few patients. The results of the present study confirm those of other authors, with better results than adults probably related to good adherence of patients and their families. Nevertheless, high cumulative doses are not necessarily related to a good response. Therefore, we suggest stopping treatment after 6 months in nonresponding cases.

AB - Phototherapy using narrowband ultraviolet B (UVB) is considered among the treatments of choice in vitiligo, even in childhood. The objective of the current study was to evaluate the profile of safety and effectiveness of such therapy in a group of children. An open, uncontrolled study was performed on 28 children with vitiligo who were receiving narrow band UVB phototherapy. The children were classified according to vitiligo type and phototype. Family history and presence of thyroid disease were investigated. Eighteen patients had received other treatments that was stopped 3 months before starting phototherapy. Phototherapy was administered twice a week. The mean duration of therapy was 10 ± 3.4 months. The mean total dose administered was 156.12 ± 79.4 J/cm 2. Photographs of lesions were taken before and at the end of treatment. The response to phototherapy was expressed as percentage of repigmentation. The data were statistically analyzed using SPSS (SPSS Inc., Chicago, IL). Fourteen percent of patients showed excellent response, 28.6% good response, 25% moderate response, and 28.6% mild response; the remaining 3.5% were not responsive. No side effects were observed except mild erythema requiring a decrease in dosage in a few patients. The results of the present study confirm those of other authors, with better results than adults probably related to good adherence of patients and their families. Nevertheless, high cumulative doses are not necessarily related to a good response. Therefore, we suggest stopping treatment after 6 months in nonresponding cases.

UR - http://www.scopus.com/inward/record.url?scp=84859102893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859102893&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1470.2011.01683.x

DO - 10.1111/j.1525-1470.2011.01683.x

M3 - Article

C2 - 22329609

AN - SCOPUS:84859102893

VL - 29

SP - 160

EP - 165

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 2

ER -